Division of Applied Life Science, BK21 Program, Plant Molecular Biology and Biotechnology Research Center (PMBBRC), Gyeongsang National University (GNU), 900 Gazwa-dong, Jinju 660-701, Republic of Korea.
Eur J Med Chem. 2011 Jun;46(6):2469-76. doi: 10.1016/j.ejmech.2011.03.035. Epub 2011 Mar 25.
Renin, an enzyme by cleaving angiotensinogen to angiotensin-I, controls the first and rate-limiting step of renin-angiotensin system that is associated with blood pressure. Thus Ligand and structure-based pharmacophore models were developed in this study to identify new potential leads inhibiting this rate-limiting enzyme as an efficient way to treat blood pressure. X-ray predicted binding modes of most active compounds were used in ligand-based approach whereas the 3D structural information of renin was used in structure-based approach. Pharmacophore models were validated using various methods and utilized in database searching to identify potential hits. Drug-like filters and molecular docking studies led us identifying the final hits to be employed in designing new class of future renin inhibitors.
肾素是一种酶,可将血管紧张素原切割成血管紧张素 I,控制肾素-血管紧张素系统的第一步和限速步骤,与血压有关。因此,本研究旨在建立基于配体和基于结构的药效团模型,以鉴定新的潜在先导化合物,作为抑制这种限速酶的有效方法来治疗高血压。基于配体的方法中使用了 X 射线预测的最活跃化合物的结合模式,而基于结构的方法则使用了肾素的 3D 结构信息。药效团模型使用各种方法进行验证,并用于数据库搜索以识别潜在的命中物。类药性筛选和分子对接研究使我们确定了最终的命中物,以用于设计新一代肾素抑制剂。